Gilead buys autoimmune biotech Ouro Medicines for up to $2.18B
What's the deal? Gilead SciencesDealroom has a profile for this one. Try Dealroom → is acquiring San Francisco-based Ouro Medicines, a clinical-stage biotech focused on autoimmune diseases, for up to $2.18B — $1.675B in cash upfront plus up to $500M in milestone payments.
The deal adds gamgertamig, an early-stage T cell engager therapy, to Gilead's growing inflammation portfolio. Gilead is also in advanced talks with Belgian biotech Galapagos on a co-development collaboration, under which Galapagos would fund half the costs and absorb most of Ouro's staff and operations.
Ouro, founded by venture capital firm Monograph CapitalDealroom has a profile for this one. Try Dealroom → in partnership with UK drugmaker GSK, only launched in 2025. But gamgertamig already holds Fast Track and Orphan Drug Designation from the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom → for two rare autoimmune blood disorders, and is expected to enter registrational studies in 2027.
Why now? Gilead's stock is up 28% year-on-year as of March 2026, giving it a $170.5B market cap — ahead of rival PfizerDealroom has a profile for this one. Try Dealroom → — and the firepower to acquire. The Ouro deal is its second major move in weeks, following the $7.8B takeover of Arcellx in February 2026.
Patent cliffs are forcing the pharmaceutical industry to replenish pipelines through M&A, and Gilead is no exception, despite facing fewer near-term expiry pressures than peers.
What could go wrong? Gamgertamig is still in Phase 1/2 trials, and early data in rare diseases don't always scale into commercial successes. The Galapagos collaboration, though reducing Gilead's financial exposure, remains subject to negotiation and could yet be renegotiated or fall through. Regulatory clearance for the acquisition itself is also pending standard conditions.
The signal: Gilead is pivoting away from its antiviral roots — HIV, hepatitis — toward inflammation and oncology. Paired with the Arcellx deal, the Ouro acquisition signals a sustained push into immunology at a moment when T cell engager therapies are gaining momentum as a novel treatment modality.
Big pharma is increasingly willing to pay a premium for early-stage, first-in-class assets, betting the clinical risk is worth taking.
Sources:
Ouro Medicines
Gilead Sciences
Fierce Biotech
Reuters
The Wall Street Journal
The Financial Times
Bloomberg
J.V.
